Stryker SYK Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| MedSurg and Neurotechnology: | $15.34B+1.0% | $15.19B+4.7% | $14.51B+3.4% | $14.03B+4.1% | $13.48B-0.3% | |
| Orthopaedics: | $9.93B0.0% | $9.92B+0.6% | $9.87B+0.9% | $9.79B+0.5% | $9.74B+7.3% | |
| Net Sales by Product | ||||||
| Endoscopy | $3.81B0.0% | $3.81B+3.8% | $3.67B+1.6% | $3.61B+3.8% | $3.48B+2.6% | |
| Hips | $1.88B+0.9% | $1.87B+2.0% | $1.83B+2.1% | $1.79B+2.2% | $1.75B+2.9% | |
| Instruments | $3.37B+2.5% | $3.29B+4.3% | $3.16B+2.6% | $3.08B+2.3% | $3.01B+6.0% | |
| Knees | $2.69B+1.2% | $2.66B+2.4% | $2.59B+2.3% | $2.54B+1.5% | $2.5B+2.1% | |
| Medical | $4.16B-1.0% | $4.2B+3.5% | $4.06B+1.2% | $4.02B+2.1% | $3.93B+2.1% | |
| Spine | $21M-88.6% | $185M-49.0% | $363M-31.4% | $529M-24.6% | $702M-0.7% | |
| Trauma and Extremities | $4.04B+2.3% | $3.95B+2.3% | $3.86B+3.0% | $3.75B+3.5% | $3.62B+3.3% | |
| Vascular | $2.08B+5.6% | $1.97B+11.2% | $1.77B+12.5% | $1.57B+12.2% | $1.4B+7.3% | |
| Net Sales by Geography | ||||||
| International | $6.23B+1.9% | $6.11B+2.8% | $5.94B+1.7% | $5.84B+1.6% | $5.75B+1.7% | |
| United States | $19.04B+0.2% | $19.01B+3.1% | $18.44B+2.6% | $17.98B+2.9% | $17.47B+3.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stryker break its business down?
- Stryker (SYK) reports net sales by business across 2 parts — MedSurg and Neurotechnology: and Orthopaedics:. Each is extracted from the segment footnotes and tracked over time.
- Where does Stryker's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stryker's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
